Trastuzumab Deruxtecan Receives FDA Approval for Metastatic HER2+ Breast Cancer
Findings from the phase 3 DESTINY-Breast03 trial have led to the FDA approval of fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.
Sara Hurvitz, MD, Spoke on Efficacy of T-DXd in HER2+ Breast Cancer With Brain Metastases
Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.
Sara Hurvitz, MD, on the Benefit of Second-Line T-DXd in Subgroups of HER2+ Breast Cancer
Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.
2 Clarke Drive Cranbury, NJ 08512